ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. — October 30, 2025 — Leads & Copy — Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced corporate highlights and unaudited financial results for Q3 2025, including the filing of an IND application for MP0712, a Radio-DARPin candidate targeting DLL3, co-developed with Orano Med, with Phase 1 initiation expected before year end 2025.
First patient images from MP0712’s compassionate care program will be presented at TRP in November. Additional programs planned for 2026 include MP0726 targeting mesothelin. Updated data from the Phase 1/2a trial of MP0533, a multispecific T cell engager for AML, will be presented at ASH in December.
The protocol has been approved for a Phase 2 investigator-initiated trial of FAP x CD40 agonist MP0317. The company has a strong financial position with cash runway until 2028.
Seth Lewis, SVP Investor Relations & Strategy, seth.lewis@molecularpartners.com, Tel: +1 781 420 2361
Laura Jeanbart, PhD, Head of Portfolio Management & Communications, laura.jeanbart@molecularpartners.com, Tel: +41 44 575 19 35
Source: Molecular Partners AG
